title: Blood pressure reduction is not the only determinant of outcome.
authors.affiliation: International Centre for Circulatory Health, Imperial College London, 59 N. Wharf Rd, London, W2 1PG, UK. p.sever@imperial.ac.uk
authors.forename: Peter S
authors.initials: PS
authors.lastname: Sever
authors.forename: Neil R
authors.initials: NR
authors.lastname: Poulter
authors.forename: William J
authors.initials: WJ
authors.lastname: Elliott
authors.forename: M Charlotte
authors.initials: MC
authors.lastname: Jonsson
authors.forename: Henry R
authors.initials: HR
authors.lastname: Black
authors.forename: Peter S
authors.initials: PS
authors.lastname: Sever
authors.forename: Neil R
authors.initials: NR
authors.lastname: Poulter
authors.forename: William J
authors.initials: WJ
authors.lastname: Elliott
authors.forename: M Charlotte
authors.initials: MC
authors.lastname: Jonsson
authors.forename: Henry R
authors.initials: HR
authors.lastname: Black
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000368:Aged; D047228:Angiotensin II Type 1 Receptor Blockers / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects*; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D019090:Case Management; D002986:Clinical Trials as Topic; D015331:Cohort Studies; D003327:Coronary Disease / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000209:etiology; D004232:Diuretics / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D004311:Double-Blind Method; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D015201:Meta-Analysis as Topic; D008875:Middle Aged; D016016:Proportional Hazards Models; D012084:Renin-Angiotensin System / Q000187:drug effects; D012306:Risk; D040242:Risk Reduction Behavior; D016896:Treatment Outcome
chemical_list: D000319:Adrenergic beta-Antagonists; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D004232:Diuretics